Parkinson's disease is a common disorder that leads to motor and cognitive disability. We performed a genome-wide association study of 2,000 individuals with Parkinson's disease (cases) and 1,986 unaffected controls from the NeuroGenetics Research Consortium (NGRC) 1-5 . We confirmed associations with SNCA 2,6-8 and MAPT 3,7-9 , replicated an association with GAK 9 (using data from the NGRC and a previous study 9 , P = 3.2 × 10 −9 ) and detected a new association with the HLA region (using data from the NGRC only, P = 2.9 × 10 −8 ), which replicated in two datasets (meta-analysis P = 1.9 × 10 −10 ). The HLA association was uniform across all genetic and environmental risk strata and was strong in sporadic (P = 5. 
is also inversely associated with cigarette smoking, caffeinated coffee consumption and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) 4, 13, 18 . Common late-onset Parkinson's disease is currently thought to result from an interplay of genetic susceptibility and environmental exposures, and data in support of this notion are beginning to emerge 5 .
A genome-wide association study (GWAS) conducted in Japanese individuals identified two new risk loci for Parkinson's disease 19 . Five GWASs have thus far been performed on individuals of European ancestry. Most of these GWASs confirmed the known associations with SNCA and MAPT, but none of them identified any new genes that reached genome-wide significance [7] [8] [9] 20, 21 . We investigated whether the genetic component in Parkinson's disease in individuals of European ancestry was due to the genes that have already been identified. Using NGRC data, we estimated heritability before and after excluding the known pathogenic and susceptibility loci. The heritability of Parkinson's disease declined from 0.6 (P < 0.0001) to 0.4 (P = 0.01) after this exclusion process but remained statistically significant, suggesting that additional unidentified risk loci existed 22 .
We performed a GWAS with 2,000 individuals with Parkinson's disease, 1,986 control subjects and 811,597 total SNPs (Supplementary Table 1 ). Subjects were recruited from the NGRC clinics in Oregon, Washington, New York and Georgia using uniform criteria for diagnosis 23 , subject selection, data collection and DNA preparation [2] [3] [4] [5] . All subjects were Americans of European ancestry. Twenty-five percent of Parkinson's disease diagnoses change within the 5.4 years following the initial diagnosis 24 ; therefore, follow-up study substantially reduces heterogeneity in the study population. The mean disease duration at enrollment was 8 years, which eliminated most early misdiagnoses, and by including an additional mean follow-up of 4 years, we were able to exclude another 47 misdiagnoses before conducting the GWAS. Controls were selected by the same investigators and from the Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease l e t t e r s same geographic regions as cases. At enrollment, the controls were on average 12 years older than the cases at disease onset, which increased our study power by reducing the likelihood that controls were at risk for disease but were too young to have yet developed symptoms. We used the Illumina HumanOmni1-Quad_v1-0_B genotyping array and achieved a call rate of 99.92% and a reproducibility rate of ≥99.99%. Association analyses were performed using PLINK V1.07 (ref. 25) . We adjusted all analyses for four covariates: age (to avoid survival bias), sex (because Parkinson's disease affects more men than women) and two principal components (PC1, PC2) that marked significant genetic substructure among Americans of European descent ( Supplementary  Fig. 1 ). Our GWAS confirmed the known Parkinson's disease susceptibility regions at SNCA (P = 3.4 × 10 −11 ) and MAPT (P = 1.3 × 10 −6 ) that we had previously reported 2, 3 .
We uncovered a new genetic association with Parkinson's disease in the HLA region (chromosome 6p21.3), which we designated PARK18. The variant most strongly associated with disease was rs3129882 in intron 1 of HLA-DRA. This association was genome-wide significant even after adjusting for the four covariates (sex, age, PC1 and PC2; P = 2.9 × 10 −8 ; Supplementary Fig. 2) . One hundred and seven HLA SNPs reached P < 10 −3 for association with Parkinson's disease. We replicated the association of rs3129882 in two independent datasets 8, 9 (meta-analysis odds ratio (OR) = 1.26, meta-analysis P = 1.9 × 10 −10 ; Table 1 ). The risk allele was the same in all datasets and was in Hardy-Weinberg equilibrium (HWE) in cases and in controls, which, in addition to the visual inspection of intensity plots, supports our belief that there were no major problems with our genotyping. Stratified analysis by family history, age at disease onset, gender and environmental exposures revealed ubiquitous associations across strata, and tests of heterogeneity across strata were not significant (Supplementary Table 2 ). Associations were particularly strong for individuals with sporadic Parkinson's disease (P = 5.5 × 10 −10 ), those with late-onset Parkinson's disease (P = 2.4 × 10 −8 ) and men (P = 1.1 × 10 −7 ). Most Parkinson's disease cases are sporadic and late onset, and Parkinson's disease affects men more than women. We found no evidence for gene-environment or gene-gene interaction between rs3129882 and smoking (P = 0.42), coffee consumption (P = 0.55), use of NSAIDs (P = 0.65), rs356220 in SNCA (P = 0.78) or rs199533 in MAPT (P = 0.24).
To look for other true signals that may not have reached genomewide significance, we performed in silico replication and metaanalysis of the most significant SNPs in the NGRC dataset (defined as P < 10 −5 ) using a publically available dataset from dbGaP (CIDR: Genome Wide Association Study in Familial Parkinson Disease) 9 . SNPs that replicated were in the HLA (including six SNPs in addition to rs3129882), SNCA and MAPT regions (Supplementary Table 3) . One SNP (rs2046571) in the HAS2 (encoding hyaluronan synthase 2) region on chromosome 8 was marginally significant in the CIDR dataset but did not reach genome-wide significance in the meta-analysis (P = 3.6 × 10 −7 ). c BST1 minor allele (freq < 0.5) in the Japanese population was the major allele in individuals of European ancestry (allele freq > 0.5). We used the same allele as reported for the Japanese population to keep the risk allele consistent. Chr3 Chr4
Chr20 Chr21
Figure 1 Genome-wide association P values. The Manhattan plot shows the P values for association of 811,597 SNPs with Parkinson's disease. SNPs that surpassed genome-wide significance (P < 5 × 10 −8 ) were on chromosomes 4 (SNCA region) and 6 (HLA-DRA). SNCA was known to be associated with Parkinson's disease; however, the association with HLA was not previously known. The other known Parkinson's disease-associated region is on chromosome 17 (MAPT region), which replicated at P = 1.3 × 10 −6 .
l e t t e r s
We used the data from NGRC to replicate findings of previous GWASs of Parkinson's disease (Supplementary Table 4) . We confirmed the association of Parkinson's disease with GAK (encoding cyclin G-associated kinase, 4p16; Supplementary Fig. 3 ), which was suggested by a previous study 9 (rs11248051 P using NGRC data only = 3.1 × 10 −4 , OR using NGRC and previous data 9 = 1.46, P using NGRC and previous data 9 = 3.2 × 10 −9 ). We designated this locus as PARK17.
Researchers from a previous study 19 reported PARK16 (1q32), BST1 (4p15) and common variants in LRRK2 (12q12) as new Parkinson's disease risk factors in the Japanese population, and an independent GWAS 7 suggested that these associations extend to individuals of European ancestry. We did not replicate PARK16 (the ORs we found were in the opposite direction to those in the published study 19 ; P = 0.03-0.15). Two of the six reported BST1 SNPs reached P < 0.05 in our data. The LRRK2 variants that were previously reported in the Caucasian study 7 were not significant in the NGRC data (P = 0.57 and P = 0.69 for the two LRRK2 variants); however, three other previously reported LRRK2 SNPs from the Japanese study 19 yielded P < 0.05 in the NGRC data, and several other LRRK2 SNPs reached P ~10 −3 . In the NGRC data, 1% of individuals with sporadic and 3% of those with familial Parkinson's disease have rare LRRK2 mutations 26 . Because LRRK2 mutations are known to cause Mendelian forms of Parkinson's disease, association between common LRRK2 variants and non-Mendelian Parkinson's disease warrants follow-up.
The SNCA, MAPT, GAK and HLA regions each have a modest effect on Parkinson's disease risk, but when considered together, the cumulative effect of these regions can be substantial ( Supplementary  Fig. 4) . To explore the combined effects of the four regions, we classified subjects by the total number of risk alleles that they carried (ranging from 0 to 8). Compared to subjects who had one or zero risk alleles, the risk of Parkinson's disease was doubled for individuals who had four risk alleles (OR = 2.49, 95% CI 1.79-3.47, P = 6.5 × 10 −8 ) and was increased fivefold for individuals who had six or more risk alleles (OR = 4.95, 95% CI 3.20-7.64, P = 5.5 × 10 −13 ). Thus, our data support the long-held notion that Parkinson's disease risk is due to cumulative effects of risk factors having modest individual effects.
A persistent problem in genetic association studies is inconsistent reproducibility, which often arises from hidden genetic variation (that is, population substructure). We investigated population substructure in depth using genomic control (λ) 27 and principal component analysis (PCA) 28 , which we augmented with self-reported ethnic and geographic origin (Supplementary Fig. 1 ). The genomic inflation factor was λ = 1.03 (Supplementary Fig. 2) . When compared to HapMap reference samples, the samples from NGRC clustered well with individuals of European ancestry. However, within the NGRC population, which is a typical mixed European American population, we found evidence for significant genetic diversity (PC1, P = 2.9 × 10 −5 , eigenvalue = 3.97; PC2, P = 0.007, eigenvalue = 1.26). Using self-reported data on ancestry, we determined that the primary clusters within NGRC correlated with Ashkenazi-Jewish and non-Jewish ancestry, and that the residual diversity in the larger non-Ashkenazi population correlated with the European country from which the subjects' ancestors had immigrated to the United States (Supplementary Fig. 1a-d) . The existence of a significant substructure within Americans of European descent has not been reported before and may be a major reason for inconsistent findings in genetic association studies. The frequency of the rs3129882 risk allele varied significantly in controls (P = 0.0007); the frequency of this allele ranged from 0.36 in Washington to 0.46 in New York. Similarly, we observed a frequency gradient across subjects from Europe; the frequency of the risk allele was low in subjects with Northern European ancestry and high in subjects with Southern European ancestry, particularly individuals of Italian descent (Supplementary Table 2) . According to the US census, 14.4% of New Yorkers are of Italian ancestry as compared to 5.6% of the population nationwide, which may explain the higher frequency of the risk allele in the population of New York. Within each subpopulation (US state or country of origin), cases had a higher frequency of the HLA risk allele than controls, which supports association of HLA with Parkinson's disease. However, because of the variable allele frequency, if the population substructure within European Americans is not taken into account, other studies may find no difference or even an inverse association of this allele with disease depending on the mixed origins of their cases and controls. Future studies of HLA and Parkinson's disease in Americans of European ancestry will therefore require careful attention to ethnic and geographic origin.
To ensure that the association with the HLA region found here was not confounded by population substructure, we corrected all analyses for the two significant principal components that marked Jewish ancestry and European country of origin. Additionally, we confirmed that the association of Parkinson's disease with rs3129882 was present in genetically defined core subsamples of both Jewish (0.04 ≤ PC1 ≤ 0.055 and 0.001 ≤ PC2 ≤ 0.013) and non-Jewish (−0.0075 ≤ PC1 ≤ 0.0025 and −0.005 ≤ PC2 ≤ 0.003) clusters (Supplementary Table 2 and Supplementary Fig. 1c) . Lower-order principal components were not significant (PC3, P = 0.32, eigenvalue = 1.11), indicating that we with the most significant SNP, rs3129882. Note that rs3129882 is not strongly correlated (defined as r 2 ≥ 0.8) with any other HLA variant. The LocusZoom software used here calculates r 2 using the HapMap European CEU data. SNPs shown in gray were on the Illumina OMNI chip but not in HapMap, and thus r 2 was not calculated with this method. However, using the Haploview software and the NGRC data to estimate r 2 , none of the variants was strongly correlated with rs3129882 (with all r 2 < 0.6; supplementary Fig. 6 ). The bottom panel shows the genes in the region, including the closely linked polymorphic HLA-DRB and DQB loci, as well as DRA, DRB5 and DRQA2, whose expression is correlated with variation at rs3129882.
identified and accounted for the bulk of genetic diversity within the NGRC population. We investigated and ruled out the concern that the association of HLA with Parkinson's disease was driven by the association of HLA with principal components (Supplementary Figs. 5 and 6 and Supplementary Table 5 ).
The HLA variant that displayed the strongest statistical association with Parkinson's disease, rs3129882, is a noncoding polymorphism in intron 1 of HLA-DRA (Fig. 2) . The protein chains encoded by the closely linked HLA-DRA and HLA-DRB form the class II HLA-DR antigens that are expressed by antigen-presenting cells, including microglia in the brain, and which interact with T-cell receptors. HLA-DRB chains are highly variable and have been associated with numerous disorders, including multiple sclerosis, which, like Parkinson's disease, is a progressive neurodegenerative disorder. HLA-DRA, on the other hand, is practically monomorphic and therefore has not been investigated for disease association. The conventional explanation for our finding is that Parkinson's disease is associated with a classical polymorphic HLA antigen and that rs3129882 is a proxy for this antigen. Alternatively, the association of Parkinson's disease with an intronic DRA variant may reflect involvement of regulatory elements, which would be in line with Parkinson's disease-specific overexpression of DR antigens in substantia nigra 29 . We used the University of Chicago's expression quantitative trait loci (eQTL) data repository (see URLs) to identify potential transcriptional variation associated with rs3129882. Two eQTL analyses, one using microarrays and the other using RNA-Seq, identified rs3129882 as a cis-acting regulatory variant that correlated significantly (P = 10 −7 to P = 10 −4 ) with expression levels of HLA-DRA, HLA-DQA2 and HLA-DRB5 (refs. 10,11). One study reported the correlation as being attributed to an exon quantitative trait locus, which suggests that the variant also affects alternative splicing 10, 11 .
The evidence for genetic association of Parkinson's disease with the HLA region, particularly when obtained from a hypothesis-free GWAS, where the entire genome is scanned without pre-existing bias towards any particular genes, lends strong and independent support to the involvement of neuroinflammation 12 and humoral immunity 30 in Parkinson's disease pathogenesis. Studies have shown elevated DR expression in the brain 29 and cerebrospinal fluid 31 of individuals with Parkinson's disease. The sustained presence of reactive DR-positive microglia has been observed in the substantia nigra of individuals with Parkinson's disease 29 , as well as animals 32 and humans 33 affected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced (MPTP) parkinsonism. It is postulated that chronic immune activation and neuroinflammation occurs in response to an initial trigger, possibly related to α-synuclein accumulation, and produces neurotoxins and oxidative damage that could kill neurons. From a therapeutic perspective, vaccination aimed at neutralizing neuroimmune dysfunction was recently shown to attenuate neurodegeneration in a Parkinson's disease model 34 ; further, NSAID use is associated with reduced risk of developing Parkinson's disease in humans 4, 13 . The newly discovered association of Parkinson's disease with the HLA region highlights the involvement of an important biological pathway in the etiology of the disease and points to a potential drug target that will stimulate research toward new therapies.
URLs. University of Chicago's eQTL data repository, http://eqtl. uchicago.edu/cgi-bin/gbrowse/eqtl/; HelixTree, http://www.golden helix.com/; LocusZoom, http://csg.sph.umich.edu/locuszoom/.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. Data are publicly available via dbGaP accession phs000196.v1.p1.
